<![CDATA[EU Approves T-DXd/Pertuzumab for Frontline HER2+ Metastatic Breast Cancer]]>
RegulatoryapprovedT-DXdPertuzumabPositive
AI Analysis
Summary
The European Commission approved T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer based on the DESTINY-Breast09 trial, representing a significant regulatory milestone for the combination treatment.
Clinical Trial Data
Outcome Details
European Commission approval for T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer
Importance:8/10
Sentiment:
0.80
breast cancerHER2-positivefirst-line therapyEU approvalDESTINY-Breast09
Related Companies
Read the original article
Published by Cancer Network on September 2, 2026 4:00 PM